Overview

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

Status:
Completed
Trial end date:
2023-07-28
Target enrollment:
Participant gender:
Summary
To evaluate whether Rodatristat Ethyl prolongs the QTc interval when orally administered to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Altavant Sciences GmbH
Collaborator:
Altasciences Clinical Kansas, Inc.
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination